Somatostatinoma
MONDO:0006976A rare, usually malignant neuroendocrine tumor arizing from delta cells. This neoplasm produces large amounts of somatostatin, which may result in a syndrome characterized by diarrhea, steatorrhea, weight loss, and gastric hyposecretion. Sixty percent are found in the pancreas and 40% in the duodenum or jejunum. The peak incidence occurs between 40 and 60 years of age; women are affected more than men by 2:1.
Also known as: Delta cell tumor, Delta cell tumour, somatostatin cell tumor, somatostatin producing tumor, somatostatin producing tumour, somatostatin-producing NET, somatostatin-producing neuroendocrine tumor, somatostatin-producing neuroendocrine tumour
1487 clinical trials for this condition and its sub-types, 6 tagged with Somatostatinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New chemo combo tested for rare gut cancers – results disappoint
Disease control OngoingThis phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control OngoingThis Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a chemo combo slow pancreatic tumor growth?
Disease control OngoingThis study tested whether adding capecitabine to the chemotherapy drug temozolomide helps people with advanced pancreatic neuroendocrine tumors live longer without their cancer growing. A total of 144 adults with tumors that could not be removed by surgery took part. The goal was…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC